Live
Alembic Pharmaceuticals associate company Rhizen Pharmaceuticals has received approval from USFDA for cancer drug.
According to a BSE release, “Rhizen Pharmaceuticals S.A. today announced that USFDA has granted orphan-drug designation for the active moiety of Tenalisib, the company’s highly selective and orally active dual PI3K delta/gamma inhibitor, for the treatment of peripheral T-cell lymphoma.”
This drug designation is given to a drug or biological product is suggested to treat a rare disease in US.
